CORDIS
EU research results

CORDIS

English EN
Integrating chemical and biological approaches to target NAD production and signaling in cancer

Integrating chemical and biological approaches to target NAD production and signaling in cancer

Objective

Deregulated nicotinamide adenine dinucleotide (NAD) biosynthesis and signaling underlies many aspects of carcinogenesis. NAD biosynthetic enzymes, such as nicotinamide phosphoribosyltransferase (NAMPT) and nicotinic acid phosphoribosyltransferase (NAPRT), are commonly upregulated in cancer cells, where they fuel increased metabolic demands and downstream enzymes involved in DNA repair and in the promotion of cell growth, cell motility, de-differentiation and immune escape. In addition, NAD-producing enzymes, such as NAMPT, moonlight in the extracellular space, exerting strongly pro-oncogenic, autocrine and paracrine effects. Many of these roles of NAD-producing and NAD-utilizing enzymes appear to be shared between solid and haematological cancers. Thus, agents targeting NAD production or signaling are expected to have broad applicability. INTEGRATA will: 1. develop new NAD biosynthesis and NAD/nucleotide signaling inhibitors; 2. assess pharmacology and toxicity of the new therapeutics in preclinical models; 3. achieve the proof-of-concept of activity of the newly generated agents in relevant in vivo cancer models. INTEGRATA will train 14 PhD students in an overarching, interdisciplinary training programme that will include training-by-research, joint courses of technical, scientific, and transferrable skills, active participation to public scientific events, and an intense intersectoral networking exchange plan. The INTEGRATA Consortium encompasses academic institutions, research centres, and SMEs/biotech pharma, all with proven experience in higher education and training, and geared with state-of-the-art scientific and technical expertise and infrastructures.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITA DEGLI STUDI DI GENOVA

Address

Via Balbi 5
16126 Genova

Italy

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 522 999,36

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITAETSKLINIKUM BONN

Germany

EU Contribution

€ 252 788,40

THE UNIVERSITY OF SHEFFIELD

United Kingdom

EU Contribution

€ 303 172,56

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Switzerland

EU Contribution

€ 281 276,64

UNIVERSITE DE GENEVE

Switzerland

EU Contribution

€ 281 276,64

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 261 499,68

UNIVERSIDAD DE SEVILLA

Spain

EU Contribution

€ 250 904,88

UNIVERSITA DEGLI STUDI DI TRENTO

Italy

EU Contribution

€ 261 499,68

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

Germany

EU Contribution

€ 252 788,40

UNIVERSITE DE MONTPELLIER

France

EU Contribution

€ 274 802,04

INNOVAMOL SRLS

Italy

EU Contribution

€ 261 499,68

NOVIMMUNE SA

Switzerland

EU Contribution

€ 281 276,64

HEIDELBERG PHARMA RESEARCH GMBH

Germany

EU Contribution

€ 252 788,40

Partners (2)

Sort alphabetically

Expand all

UNIVERSITE DE LAUSANNE

INNOVATION ACTA S.R.L.

Project information

Grant agreement ID: 813284

Status

Ongoing project

  • Start date

    1 November 2018

  • End date

    31 October 2022

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 738 573

  • EU contribution

    € 3 738 573

Coordinated by:

UNIVERSITA DEGLI STUDI DI GENOVA

Italy